Pharma BD Deal Intelligence

Hikma Pharmaceuticals PLC / Boehringer Ingelheim (Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc.)

2015 · Acquisition/Merger · $2.6B · Complete

Announcement Sentiment

Positive

Hikma agreed to acquire Roxane Laboratories from Boehringer Ingelheim for $1.18B cash plus 40M new Hikma shares (~$2.6B aggregate) plus up to $125M contingent payments. Closed February 29, 2016 with cash portion reduced by $535M to ~$647M due to lower 2015 revenue. Made Hikma the sixth-largest US generics company.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Impaired/Written Down

Pipeline outcome

Mixed

Assessment window: 5yr post-close.

Key facts

Announced Jul 28, 2015
Closed Feb 29, 2016
Deal value $2.6B
Deal type Acquisition/Merger
Therapeutic area Multiple (oncology, respiratory, CNS)
Indications Multiple (oncology, respiratory, CNS)
Key assets US specialty generics portfolio (88 products including oncology, respiratory, controlled substances)
Mechanism Generic small molecules and sterile injectables

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals